Search PubMed⌕ Search

Biomedical subjects

C Rivat

Publications and source records attributed to C Rivat.

At least 37 records · Page 2Linked to original sources

[Human plasma fibronectin. Comparison of methods for preparation of a concentrate for therapeutic use from different sources].

Three methods, successive precipitations, affinity chromatography on immobilized gelatin and immunoaffinity chromatography with monoclonal anti-fibronectin antibodies were optimized and compared in order to be used for large scale preparation of human plasma fibronectin (Fn). The functional properties of the various Fn preparations were investigated by means of two assays: quantitation of the gelatin-binding activity by ELISA and quantitation of the Fn-mediated attachment of fibroblasts on plastic. Functional alterations of the purified Fn were observed when it was isolated by successive precipitations. Both chromatographic methods provide a rapid and convenient way for isolation of pure and functional Fn. Mass production of monoclonal antibodies is too expensive and legislative requirements for the therapeutic use of monoclonal antibodies are limiting factors for the choice of immunopurification as large scale isolation procedure. Plasma Fn can be isolated from different sources: fresh frozen plasma, cryoprecipitate supernatant or by-products from factor VIII preparation. When gelatin-Sepharose chromatography is performed under optimized conditions, fibronectins isolated from these sources show similar properties. Large scale purifications of Fn from a by-product of factor VIII preparation were performed either by gelatin affinity chromatography or by successive precipitations. These two purification methods can be easily scaled-up since the data obtained closely correlate with analytical results. The chromatographic method supplies a higher purified (98 vs 75%) and functional (95 vs 50%) material when compared with successive precipitations. Yield is also higher (50 vs 26%). The starting material undergoes viral inactivation and the affinity purified Fn, sterile, atoxic, apyrogen, which can be freeze-dried without additives fulfils all requirements for an injectable product.

Antibodies, Monoclonal↗

[Development of a technique of immunoadsorption of LDL-cholesterol].

An immunoadsorption system for lowering plasma cholesterol was optimized. Several polyclonal and monoclonal antibodies were compared and the best results were obtained with goat polyclonal antibodies. The optimum quantity of antibodies to be immobilized on the gel was 5 mg/ml. Taking into account two variables, i.e., 1) that the regeneration must be as complete as possible and, 2) that immunoadsorbents must be used several times without a loss of adsorption capacity, desorption was achieved with 0.3 M glycine adjusted to pH 2.8. Antibody release from the immunoadsorbent was determined and can be minimized by glutaraldehyde treatment of the immunoadsorbent. Each phase, adsorption and desorption, respectively, was well-defined and synchronized, so that two columns could be used in parallel in an automated procedure. The kinetics of plasma protein removal demonstrated the efficiency and the specificity of the procedure.

Animals↗

Study of parameters involved in specific immunoadsorption of apolipoprotein B.

A therapeutic immunoadsorption system on immobilized and anti-apolipoprotein B as a plasma cholesterol lowering procedure was optimized. Several antibodies were compared and highest adsorption capacity was obtained with goat polyclonal antibodies. Optimum quantities of antibodies to be immobilized on the gel and quantities of apo-B to be applied to columns were determined. The amount of antibodies released from immunoadsorbents can be minimized by treatment with a 0.005% glutaraldehyde solution with an acceptable reduction rate of adsorption capacity. Each phase, adsorption and desorption respectively, were well-defined and synchronized so two columns could be used in parallel in an automated procedure. In these conditions, the immunoadsorption system can efficiently, specifically and safely remove cholesterol and has to be subjected to clinical trials.

Animals↗

Biotechnology of plasma proteins. Fractionation and applications.

Without discussing all of the current problems of industrial plasma fractionation, this INSERM International Symposium emphasized the importance of the technological progress of the last ten years. Although Cohn's classical technique of alcohol precipitation is still the most widely used, new techniques are rapidly being developed based on more selective methods with high extraction yields. However, it is certain that, given the growth in biotechnologies with the industrial applications of genetic engineering and cellular engineering, various problems will eventually be raised concerning plasma fractionation. It is probable that in the relatively near future certain fractions such as F VIII will no longer be prepared from plasma; but can the other fractions be reasonably replaced in the foreseeable future? Furthermore, the problems of purification will always be the crux of the development of biotechnologies. The technical committee of the OECD has recently drawn the attention of European governments to the considerable importance for the future of bioindustries of 'downstream processings' and the need to develop research on methods of extraction and purification. Human plasma is certainly the ideal model for the development of new methods of protein purification which could subsequently be applied to other industrial fields such as cellular engineering or genetic engineering. European countries definitely have an edge in this field as a result of their industries and fractionation centers.

Biotechnology↗

Affinity purification of human plasma fibronectin on immobilized gelatin.

Several problems are associated with the biospecific affinity purification of plasma fibronectin on gelatin-Sepharose. Large-scale development of this purification procedure requires optimization of adsorption and elution conditions. The adsorption capacity depends on the amount of gelatin coupled to the Sepharose, the residence time, the temperature and the amount of fibronectin loaded on the adsorbent. Elution of adsorbed fibronectin with 3 M urea leads to incomplete recovery. The elution yield was found to vary with both the gelatin concentration and the amount of adsorbed fibronectin. Despite the incomplete elution, the adsorption capacity did not decrease after twelve consecutive isolation procedures. Under optimized conditions, the method described here provides a rapid, single-step and convenient way for the isolation of pure and functional fibronectin, either for analytical or large-scale preparative purposes.

Adsorption↗

[Highly purified, functionally active human fibronectin preparation].

Fibronectin has been purified by gelatin-Sepharose affinity chromatography from fresh frozen human plasma. The bound fibronectin was eluted with 3 M urea. The purity of the fibronectin obtained has been checked on (immunoelectrophoresis, polyacrylamide gel electrophoresis, FPLC). Biological activity of the purified molecule has been monitored by means of three assays: quantitation of the gelatin-binding activity by ELISA, quantitation of the fibronectin-mediated attachment of fibroblasts on plastic and evaluation of the opsonic activity (uptake of gelatin latex particles by a murine macrophage line). When deep-frozen, fibronectin retains all of its properties. This highly purified and functional fibronectin fulfills the basic requirements for a standard reagent. It will allow to investigate physicochemical and functional alterations of various fibronectins.

Cell Adhesion↗

[Immunosorption of apolipoproteins B. Optimization of the method in an in vitro bench test].

The aim of the present study was to determine optimum conditions for preparation and use of immunoadsorbents for removal of apolipoprotein B from plasma. An in vitro study was carried out to optimize different chromatography parameters: linear flow rate, apo B quantity loaded, gel regeneration conditions. Specificity of removal of apo B, stability of antibody covalent linkage and possible multiple use of immunoadsorbents were assessed. No significant loss of adsorption capacity was observed after sterilization and storage of immunoadsorbents.

Apolipoproteins B↗

A potential new procedure for removing anti-factor VIII antibodies from hemophilic plasma.

A new approach for removing the anti-factor VIII antibodies in hemophilic patients by immunoadsorption is proposed. The method is based on the fact that the anti-factor VIII antibodies were predominantly of the IgG4 subclass; anti-human IgG4 antibodies were covalently linked to agarose and large amounts of anti-factor VIII antibodies can be eliminated. A study of 21 blood samples from hemophilic patients with anti-factor VIII antibodies allows us to confirm the large predominance of IgG4 in the anti-factor VIII population. In some samples, the presence of IgG3 related anti-VIII:C was checked by adsorption on an anti-IgG3 column. In a majority of cases, after IgG4 (or IgG4 + IgG3) immunoadsorption, the substitution therapy becomes possible or easier.

Antibody Specificity↗

Genetic variants of factor B in a population of Jordan.

BF phenotyping was performed in a population of Jordan. The observed allele frequencies were as follows: BF*S = 0.5457, BF*F = 0.3744, BF*SO7 = 0.0763, BF*F1 = 0.0075. These values are in agreement with the geographic position and the ethnic composition of Jordan.

Complement Factor B↗

An extracorporeal hollow-fiber reactor for phenylketonuria using immobilized phenylalanine ammonia lyase.

A hollow-fiber hemodialyzer with immobilized phenylalanine ammonia lyase was tested in vitro for depletion of blood phenylalanine in a recirculating system. A sustained reduction of phenylalanine was obtained in less than 1 h. The product of phenylalanine deamination, trans-cinnamic acid, is a nontoxic compound metabolized to benzoic acid by the liver and eliminated in the urine as hippuric acid. As a model, this reactor may be relevant not only for the short-term management of hyperphenylalaninemia (particularly in pregnant phenylketonuric mothers), but for other metabolic diseases as well, provided that a biocatalyst effective on the accumulating substance is available.

Ammonia-Lyases↗

C3, BF and C4 polymorphisms in familial Mediterranean fever.

BF, C3 and C4 phenotyping were investigated in 34 patients with familial Mediterranean fever (FMF) and in 48 control subjects. Both groups included Sephardic Jews born in Tunisia, Algeria and Morocco. No linkage between BF, C3 and C4 polymorphisms and FMF was found.

Alleles↗

Suitable hollow fibre immunobioreactors for specific ex vivo removal of antibodies and antigens from plasma.

Studies were undertaken to determine the applicability and effectiveness of a new immunoadsorbent, constituted of cellulose hollow fibres chemically modified (BrCN) to link selected proteins. The method has been assayed on a simple model of antibody elimination: myeloma IgG or BSA as antigens were covalently linked to cellulose; such an immunoadsorbent can selectively and efficiently deplete circulating antibodies in vitro and ex vivo (on immunized dogs) from whole blood, without releasing linked protein into the hosts' circulation. The original approach of using this method to remove antibodies has been extended to specifically remove antigens (for this purpose, antibodies were conjugated to cellulose), in order to investigate an immunoadsorption therapy in familial hypercholesterolemia, characterized by a plasmatic overload of low-density-lipoproteins (LDL), of which apolipoprotein B is the major protein. After covalent linkage of isolated anti-apolipoprotein B antibodies to cellulose, human plasma LDL levels were effectively and specifically reduced by this procedure.

Animals↗

Inulin-induced activation of factor B in whole serum: description of structural modifications in the Ba fragment.

The investigation of inulin-induced conversion of human factor B in serum by isoelectrofocusing revealed physiological modifications in the primary structure of the Ba fragment. Evidence has been obtained that a nascent Ba, generated by the hydrolytic action of the D component on B in serum, was a short-lived product and that a fast release of carboxy-terminal arginine and lysine residues occurred involving a serum carboxypeptidase B enzyme.

3-Mercaptopropionic Acid↗

Genetic variants of human B component (BF system) and alpha-1-antitrypsin (PI system) in a population from Sardinia.

BF- and PI-type determinations have been performed in a population from Sardinia. The corresponding allele frequencies are as follows: BF*S = 0.5783, BF*F = 0.2189, BF*SO7 = 0.0046, BF*F1 = 0.1982 and PI*M1 = 0.5872, PI*M2 = 0.2041, PI*M3 = 0.0459, PI*M4 = 0.0940, PI*S = 0.0619, PI*Z = 0.0046, PI*N = 0.0023. Whereas the BF system shows the originality of the Sardinian population with a very high BF*F1 allele frequency, the PI system does not reveal any characteristic features.

Alleles↗

HLA A*, B*-BF* and C4 A*, B* allele associations, with special reference to BF*S07, in the Tunisian population.

The HLA A*2, Bw*50-BF*S07-C4 A*2, B*1 linkage group was transmitted unambiguously in four unrelated Tunisian families. In one of these, another allele association, also carrying BF*S07, HLA A*9, Bw*50-BF*S07-C4 A*1, B*1, was encountered. The previously reported linkage disequilibrium between BF*S07 and HLA Bw*50, a subtypic specificity of HLA Bw*21, is confirmed in our study. The C4 A*2, B*1 haplotype, rare in the other populations until now studied, seems more frequent in Tunisia since it has been also found linked to HLA A*11, B*27 and BF*S in one of these families. Other allele associations were unambiguously demonstrated with predominantly the C4 A*3, B*1 haplotype, particularly a rare HLA A*3, B*18-BF*F1-C4 A*3, B*1 linkage group. A silent gene at the C4 A locus was found linked to HLA B*8.

Alleles↗